Abstract
In a recent eBioMedicine publication, Fulford et al. reported the development of a point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2. In “Evidence before this study”, the authors stated that PubMed literature searches, including MedRxiv pre-print servers as well as manual searches in relevant papers up to 11 October 2021, did not reveal prior reports of “deployable, visual point of care test for measuring levels of protective levels of SARS-CoV-2 protection.1Fulford T.S. Van H. Gherardin N.A. et al.A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.EBioMedicine. 2021; 74103729https://doi.org/10.1016/j.ebiom.2021.103729Summary Full Text Full Text PDF PubMed Scopus (11) Google Scholar“ This statement is incorrect because the authors reference our MedRxiv pre-print, “Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2,” in reference 18, indicating that our paper preceded theirs. Indeed, our manuscript was available on MedRxiv since December 2020 with doi:https://doi.org/10.1101/2020.12.15.20248264, prior to Fulford's et al. report. Of note, our paper is published in December 2021, Volume 145 issue of Journal Clinical Virology.2Lake D.F. Roeder A.J. Kaleta E. et al.Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2.J Clin Virol. 2021; 145105024https://doi.org/10.1016/j.jcv.2021.105024Crossref PubMed Scopus (10) Google ScholarWe completely agree with Fulford's assertion that tests which measure levels of neutralizing antibodies are critical for determining correlates of protection in vaccine recipients. Because antibody levels decline over time, functional tests such as ours and Fulford's could be used to determine when individuals are no longer protected from infection and can make an informed choice to receive a booster vaccination. Additionally, we believe every vaccine recipient has a right to know how well their vaccine induced protective antibodies.ContributorsDFL wrote this Letter in consultation with AJR, AS-N, MJG-M and SS who each participated editing the Letter. In a recent eBioMedicine publication, Fulford et al. reported the development of a point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2. In “Evidence before this study”, the authors stated that PubMed literature searches, including MedRxiv pre-print servers as well as manual searches in relevant papers up to 11 October 2021, did not reveal prior reports of “deployable, visual point of care test for measuring levels of protective levels of SARS-CoV-2 protection.1Fulford T.S. Van H. Gherardin N.A. et al.A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2.EBioMedicine. 2021; 74103729https://doi.org/10.1016/j.ebiom.2021.103729Summary Full Text Full Text PDF PubMed Scopus (11) Google Scholar“ This statement is incorrect because the authors reference our MedRxiv pre-print, “Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2,” in reference 18, indicating that our paper preceded theirs. Indeed, our manuscript was available on MedRxiv since December 2020 with doi:https://doi.org/10.1101/2020.12.15.20248264, prior to Fulford's et al. report. Of note, our paper is published in December 2021, Volume 145 issue of Journal Clinical Virology.2Lake D.F. Roeder A.J. Kaleta E. et al.Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2.J Clin Virol. 2021; 145105024https://doi.org/10.1016/j.jcv.2021.105024Crossref PubMed Scopus (10) Google Scholar We completely agree with Fulford's assertion that tests which measure levels of neutralizing antibodies are critical for determining correlates of protection in vaccine recipients. Because antibody levels decline over time, functional tests such as ours and Fulford's could be used to determine when individuals are no longer protected from infection and can make an informed choice to receive a booster vaccination. Additionally, we believe every vaccine recipient has a right to know how well their vaccine induced protective antibodies. ContributorsDFL wrote this Letter in consultation with AJR, AS-N, MJG-M and SS who each participated editing the Letter. DFL wrote this Letter in consultation with AJR, AS-N, MJG-M and SS who each participated editing the Letter. DFL receives grant support from Axim Biotechnologies, AS-N, MJG-M and SS are employees of Axim Biotechnologies. AJR has no competing interests. Letter to the editor RE: Lake et al., 2022 comment on Fulford et al., 2021 ‘A point-of-care lateral flow assay for neutralizing antibodies against SARS-CoV-2’In our recent eBioMedicine publication1 we included the statement in “Evidence before this study” that PubMed literature searches, including MedRxiv pre-print servers as well as manual searches in relevant papers up to 11 October 2021, did not reveal prior reports of “deployable, visual point of care test for measuring levels of protective levels of SARS-CoV-2 protection”. Full-Text PDF Open Access
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
